Galapagos Could Give Up On Jyseleca Over JAK Class Woes

The rollercoaster ride for investors in Galapagos NV has taken another turn with the Belgium-headquartered biotech revealing that it is weighing up all options for its only approved product, the JAK inhibitor Jyseleca.

Galapagos has unveiled its financials for the first half which show that Jyseleca (filgotinib), approved in Europe for rheumatoid arthritis and ulcerative colitis, reached €54.3m in sales, up by 54% on the like, year-earlier period but some way below consensus estimates. The decline was due to the European Commission's endorsement of the recommendation of its Pharmaceutical Risk Assessment Committee, following similar guidance in the US, to place restrictions on the use of all drugs in the JAK inhibitor class in certain patient groups including those aged 65 years or older